Yale School of Medicine

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

“It’s important to realize that a single TikTok post can reach tens of thousands of people and potentially influence health care decisions," says Leslie Rickey, MD, MPH.

"The scale of that linkage and the manner with which we were able to do it is really exciting and opens the door for a lot of future discovery," says Michael S. Leapman, MD, MHS.

For the third consecutive year, Yale Medicine Urology, in connection with Yale New Haven Hospital, has been ranked nationally on U.S. News & World Report’s “Best Hospitals Adult Specialty” list.

"This information, and future expansions of this work could help refine the ways in which key clinical decisions are made..." says Michael S. Leapman, MD, MHS.

Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.

“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.

"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.

Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.

"We identified that in our site, we were ordering almost 1600 cystoscopy packs. A lot of the materials that were in those packages were unnecessary for an outpatient procedure," says Malissa Williams.

"I think people don't understand how exhausting it is for people to manage these symptoms day in and day out," says Leslie Rickey, MD, MPH.

"This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles," says Daniel P. Petrylak, MD.

“It's important to note as well that the kidney cancer biology is really distinct from a lot of other solid tumors, and particularly other immunotherapy response to solid tumors,” says David A. Braun, MD, PhD.

"What we found is that there was rapid adoption and uptake of PSMA PET almost immediately after these agents were first approved in the United States," says Michael S. Leapman, MD, MHS.

"This is just another way that we can exploit the body's own natural system to take care of cancer," says Daniel P. Petrylak, MD.

"I think that, across industries, AI is going to provide a great benefit to our day-to-day practice," says Michael Karellas, MD.

"It's really gratifying to see how the field has changed over the last 10 years," says Daniel P. Petrylak, MD.

"PLUS was created to start laying down the foundation for implementing prevention science, and understanding things that helped maintain bladder health [and] things that are risk factors for progression into bladder disease," says Leslie Rickey, MD, MPH.

Immunotherapy initiation within 1 month of death for patients with renal cell carcinoma increased from 0.5% to 2.6% over the course of the study.

"What we found is that overall, it was relatively effective at providing advice to patients on these pretty commonly encountered questions," says Sharath Reddy, MD.

"In general, I think there's a tremendous amount of variability in terms of how sexual medicine specialists treat patients who have had intimacy issues relating to robotic prostatectomy," says Stanton Honig, MD.

Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.

"I think what should be more appropriate is that the initial treatment decision does not impact [survival], but I don't think you can say that intervening aggressively for this lethal disease does not alter the course," says Isaac Y. Kim, MD, PhD, MBA.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

Yale Urology Chair Isaac Y. Kim, MD, PhD, MBA, has published his concerns surrounding interpreted results in the landmark ProtecT Study.

Expert urologist Michael S. Leapman, MD, MHS, provides comprehensive insight to the classification of prostate cancer and current treatment modalities available to patients.

“The medication is given once a week for 6 weeks. It is an outpatient procedure with general anesthesia. And it is typically covered by insurance,” said Joseph Brito, MD.

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.